Potential ROI With German Biopharma Co. Notable
Source: Dr. Elemer Piros  (10/27/22)
This firm, with eight treatment candidates for mental health disorders in development, boasts a catalyst-rich next two months, noted a ROTH Capital Partners report. More >

Vaccine Co. Posts Positive Ph. 1/2 IPD Trial Results
Source: Streetwise Reports  (10/25/22)
Shares of Vaxcyte Inc. traded 61% higher yesterday to a new 52-week high after the company reported positive topline results from its Phase 1/2 study of VAX-24, its novel 24-valent pneumococcal conjugate vaccine candidate being developed to prevent invasive pneumococcal disease in adults 18 to 64 years of age. More >

Expert Says Buy Pharma Co. Stock 'as Soon as Possible'
Source: Clive Maund  (10/25/22)
Algernon Pharmaceuticals has entered into a clinical trial agreement with Yale and caught expert Clive Maund's attention. In light of this, Maund reviews the company's chart to tell you when he believes you should buy its stock. More >

Biopharma Co. Shows Large Potential Return
Source: Dr. Joseph Pantginis   (10/21/22)
Palatin Technologies Inc.'s third-party clinical trial of Vyleesi in women with hypoactive sexual desire disorder was just published in the Journal of Clinical Investigation, and the biopharma offers investors significant potential return, noted an H.C. Wainwright & Co. report. More >

Biotech Co.'s Target Price Over Three Times Current
Source: Dr. Joseph Pantginis   (10/13/22)
Expanded interim data from the Phase 2 trial of this biotech's lead asset PDS0101 in HPV16-associated cancers are consistent with previously reported results from the same study. Read more to discover why H.C Wainright & Co. believes this stock is a Buy with a target price over three times the current. More >

Biopharma Co. Partners With Merck for Combo Drug Trial
Source: Dr. Joseph Pantginis  (10/12/22)
With this and other clinical studies, the U.S. company has a busy and, thus, catalyst-rich Q4/22 ahead, noted an H.C. Wainwright & Co. report. More >

Biopharma Co.'s Shares Roll to New 52-Week High Price
Source: Streetwise Reports  (10/12/22)
Shares of DICE Therapeutics Inc. traded 62% higher yesterday and established a new 52-week intraday high after the company reported positive topline data from its Phase 1 DC-806 Psoriasis study. More >

Chen Reveals His Picks for Last Quarter
Source: Streetwise Reports  (10/11/22)
Asset manager Chen Lin's picks for the home stretch of 2022 include several biotechs and some precious metals companies. More >

US Firm Teams up With Leading Pharma Co. To Delay T1D Onset
Source: Streetwise Reports  (10/7/22)
Provention Bio Inc.'s shares traded 25% higher yesterday after the company reported it is joining forces with Sanofi U.S. to support the potential upcoming U.S. launch of its teplizumab for use in delaying the onset of clinical type 1 diabetes in at-risk patients. The U.S. FDA is expected to rule on the firm's Biologics License Application in mid-November 2022. More >

Biotech Co.'s Drug Showing 'Early Signs of Benefit'
Source: Dr. Elemer Piros  (10/6/22)
With this upcoming analysis, the board will determine whether the Phase 2b/3 trial may continue to completion, noted a ROTH Capital Partners report. More >

Trial Results of New Drug for An Eye Disease 'Encouraging'
Source: Dr. Yale Jen  (10/6/22)
The data suggest this treatment could be safer and more effective in treating proliferative vitreoretinopathy than compounded methotrexate, noted a Laidlaw & Co. report. More >

Co. Uses RNA Editing as Treatment for Rare Disease
Source: Andrew Fein  (10/3/22)
The firm plans to advance its alpha-1 antitrypsin deficiency program into the clinic next year, noted an H.C. Wainwright & Co. report. More >

Interim Results From Phase 2b Trial Are 'Encouraging'
Source: Dr. Elemer Piros  (9/30/22)
Data show the biotech's compound had a positive effect on several noninvasive measures, noted a ROTH Capital Partners report. More >

Biopharma Co. Awarded FDA Clearance for Advanced Solid Tumors Trial
Source: Streetwise Reports  (9/30/22)
Shares of oncology-focused biopharmaceutical company Immuneering Corp. traded 9% higher after the firm reported it received U.S. FDA clearance for its IND Application for a Phase 1/2a clinical trial of IMM-1-104 for use in treatment of advanced solid tumors with RAS mutations. The company expects to enroll the first patient in the study in Q4/22. More >

Pharma Co. Meets Primary Endpoint in Phase 3 Alzheimer's Trial
Source: Streetwise Reports  (9/29/22)
Shares of Eisai Co. Ltd. traded 58% higher yesterday after the company reported topline data from its global Phase 3 clinical study demonstrating that its lecanemab significantly met the primary and key secondary endpoints in reducing mild cognitive impairment due to Alzheimer's disease. More >

Biopharma Asks for Emergent Use in US of New COVID Drug
Source: Edward White  (9/29/22)
The requested approval is specifically for critically ill patients, a population for which the U.S. Food and Drug Administration granted the therapeutic fast track status, noted an H.C. Wainwright & Co. report. More >

Oncology Co.'s Shares Erupt on Signing Global License Deal
Source: Streetwise Reports  (9/27/22)
Shares of clinical-stage immuno-oncology company LAVA Therapeutics NV traded nearly 100% higher yesterday after the firm reported that it has entered into a global licensing agreement with Seagen Inc. to advance its LAVA-1223, a preclinical gamma delta bispecific T cell engager designed for use in the treatment of EGFR-expressing solid tumors. More >

Co.'s Clinical Program in HPV+ Cancers Gives It a Buy Rating
Source: Dr. Joseph Pantginis  (9/23/22)
To fund continued development of its lead immunotherapy candidate, the U.S.-based biopharma recently completed a $35 million debt financing agreement, noted an H.C. Wainwright & Co. report. More >

Analyst Says Buy Before Biotech Co.'s Clinical Trials
Source: Dr. David Nierengarten  (9/23/22)
Argenx SE has "several upcoming catalysts," noted a Wedbush report. More >

FDA Approves Hearing Loss Drug for Child Chemo Patients
Source: Streetwise Reports  (9/21/22)
Shares of Fennec Pharmaceuticals Inc. traded 14% higher after the company reported it received approval from the U.S. FDA for its PEDMARK® (sodium thiosulfate injection) for use in reducing the risk of ototoxicity in pediatric patients who are undergoing or completed chemotherapy for non-metastatic solid tumors. More >

Dermatology Co.'s Target Price Much Higher Than Current
Source: Dr. Jonathan Aschoff  (9/20/22)
The biopharma's strategic marketing campaign "should continue growing U.S. sales to current and new customers," noted a ROTH Capital Partners report. More >

Important Catalyst Expected Soon for Cancer Drug Co.
Source: Dr. David Nierengarten  (9/20/22)
The biopharma should announce initial clinical trial data on its lead small molecule candidate by year-end, noted a Wedbush report. More >

Biopharma Co.'s Shares Rise on Phase 3 Migraine Trial Data
Source: Streetwise Reports  (9/20/22)
Satsuma Pharmaceuticals Inc. shares traded 12% higher to a new 52-week high after the company reported positive results from its Phase 3 long-term study of STS101 for use in acute treatment of migraine attacks. The company expects to receive further efficacy data from its Phase 3 SUMMIT trial in Q4/22, which it believes will support submission of an NDA with the U.S. FDA in Q1/23. More >

Second Trial of New Eczema Drug To Commence in Q4/22
Source: Dr. Yi Chen  (9/17/22)
The purpose behind this complementary study is to potentially expand the treatment's target patient population, noted an H.C. Wainwright & Co. report. More >

FDA Grants Approval for Drug Improving Kidney Function
Source: Streetwise Reports  (9/16/22)
Shares of Mallinckrodt Plc. traded 28% higher yesterday after the company reported that the U.S. FDA has issued approval for its Terlivaz® (terlipressin) for injection for use in treating hepatorenal syndrome, a serious and life-threatening condition that is accompanied by rapid reduction in kidney function. More >